Tag
A 2026 PLOS One superiority trial found that internet-based vestibular rehabilitation was not superior to structured written instructions after acute vertigo. The result is clinically useful because the comparator was active, adherence was
A national U.S. study found that patients with epilepsy from rural counties had worse hospital outcomes, including higher mortality, more status epilepticus, longer stays, and less EEG use, highlighting access-related disparities.
In a Swedish randomized trial, low-dose acetazolamide did not improve gait in patients with idiopathic normal pressure hydrocephalus and caused more side effects than placebo, arguing against routine use as medical therapy.
In a phase 3 trial, once-daily tavapadon improved motor symptoms in people with early Parkinson disease and was generally well tolerated, with nausea, headache, and dizziness as the most common side effects.
In adults with MOGAD, stopping maintenance therapy was associated with a low 1-year relapse risk, especially after longer treatment and a longer relapse-free interval. The findings support individualized decisions and close follow-up after
The SECRETO study reveals that infections within the preceding week significantly increase the risk of cryptogenic ischemic stroke in patients aged 18–49, with elevated von Willebrand Factor and Factor VIII levels serving as critical biomar
A pooled analysis of 11,269 patients from the INTERACT and ATACH-II trials reveals that 24-hour systolic blood pressure trajectories, rather than just single targets, significantly influence functional outcomes after intracerebral hemorrhag
A retrospective study of 489,360 patients reveals that right-sided middle cerebral artery strokes are associated with significantly higher inpatient mortality and complications compared to left-sided strokes, likely due to inherent scoring
A large-scale longitudinal study reveals that motor vehicle accidents cause significantly worse acute traumatic brain injury outcomes compared to falls. However, by one year post-injury, disability levels and community participation converg
This retrospective study identifies a high prevalence of spinal cord p-tau and protein copathologies in patients with Chronic Traumatic Encephalopathy (CTE), suggesting the existence of a ‘trauma-related encephalomyelopathy’ lin
This translational study demonstrates that the FKBP5 protein, a regulator of the stress response, significantly influences stroke outcomes. Lower FKBP5 levels correlate with smaller brain lesions in mice, while high-expression genetic varia
Researchers have discovered that mutations in the SNUPN gene cause spinocerebellar atrophy by disrupting RNA splicing in Purkinje cells, expanding the understanding of neurodevelopmental disorders beyond muscular conditions.
This article examines a Phase 2a trial investigating eslicarbazepine acetate for preventing post-stroke epilepsy. While the primary endpoint was not met due to recruitment challenges, the study provides a critical framework for future antie
The EMPHASIS trial reveals that oral minocycline initiated within 72 hours of an acute ischaemic stroke significantly enhances functional independence at 90 days. This multicentre study provides robust evidence for a well-tolerated, accessi
A Phase 1-2 trial of AAV9-GLB1 gene therapy in children with Type II GM1 gangliosidosis demonstrates significant biochemical improvements and stabilization of neurodevelopmental decline, marking a pivotal step toward treating this fatal lys
A five-year prospective study reveals that 13.6% of stroke patients with mild cognitive impairment progress to major VCI, identifying age, diabetes, atrial fibrillation, and small vessel disease as key predictors for long-term cognitive dec
A prospective study of over 130,000 adults reveals that consuming 2-3 cups of caffeinated coffee or 1-2 cups of tea daily significantly reduces dementia risk and cognitive decline, whereas decaffeinated coffee shows no protective effect.
Brazilian scientists have developed Polylaminin, a protein derived from human placenta that stimulates nerve regeneration. In early trials, six paralyzed patients regained the ability to walk, prompting official Phase I clinical trials to b
An exploratory analysis from the ARCADIA-MRI substudy reveals that apixaban carries a similar risk of incident intracranial hemorrhages, microbleeds, and superficial siderosis compared to aspirin in patients with atrial cardiopathy and cryp
A secondary analysis of the PRESTIGE-AF trial reveals that specific MRI markers, including cortical superficial siderosis and macrohemorrhages, are more potent predictors of recurrent intracerebral hemorrhage than hematoma location alone, o
